• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

BMJ . Clinical spectrum of coronavirus disease 2019 in Iceland: population based cohort study

tetano

Editor, Senior Moderator
BMJ


. 2020 Dec 2;371:m4529.
doi: 10.1136/bmj.m4529.
Clinical spectrum of coronavirus disease 2019 in Iceland: population based cohort study


Elias Eythorsson[SUP] 1 [/SUP], Dadi Helgason[SUP] 1 [/SUP], Ragnar Freyr Ingvarsson[SUP] 1 [/SUP], Helgi K Bjornsson[SUP] 1 [/SUP], Lovisa Bjork Olafsdottir[SUP] 1 [/SUP], Valgerdur Bjarnadottir[SUP] 1 [/SUP], Hrafnhildur Linnet Runolfsdottir[SUP] 1 [/SUP], Solveig Bjarnadottir[SUP] 1 2 [/SUP], Arnar Snaer Agustsson[SUP] 1 [/SUP], Kristin Oskarsdottir[SUP] 1 [/SUP], Hrafn Hliddal Thorvaldsson[SUP] 1 [/SUP], Gudrun Kristjansdottir[SUP] 1 2 [/SUP], Brynja Armannsdottir[SUP] 1 [/SUP], Agnar Bjarnason[SUP] 1 2 [/SUP], Birgir Johannsson[SUP] 1 [/SUP], Olafur Gudlaugsson[SUP] 1 [/SUP], Magnus Gottfredsson[SUP] 1 2 [/SUP], Martin I Sigurdsson[SUP] 1 2 [/SUP], Olafur S Indridason[SUP] 1 [/SUP], Runolfur Palsson[SUP] 3 2 [/SUP]



Affiliations

Abstract

Objective: To characterise the symptoms of coronavirus disease 2019 (covid-19).
Design: Population based cohort study.
Setting: Iceland.
Participants: All individuals who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by reverse transcription polymerase chain reaction (RT-PCR) between 17 March and 30 April 2020. Cases were identified by three testing strategies: targeted testing guided by clinical suspicion, open invitation population screening based on self referral, and random population screening. All identified cases were enrolled in a telehealth monitoring service, and symptoms were systematically monitored from diagnosis to recovery.
Main outcome measures: Occurrence of one or more of 19 predefined symptoms during follow-up.
Results: Among 1564 people positive for SARS-CoV-2, the most common presenting symptoms were myalgia (55%), headache (51%), and non-productive cough (49%). At the time of diagnosis, 83 (5.3%) individuals reported no symptoms, of whom 49 (59%) remained asymptomatic during follow-up. At diagnosis, 216 (14%) and 349 (22%) people did not meet the case definition of the Centers for Disease Control and Prevention and the World Health Organization, respectively. Most (67%) of the SARS-CoV-2-positive patients had mild symptoms throughout the course of their disease.
Conclusion: In the setting of broad access to RT-PCR testing, most SARS-CoV-2-positive people were found to have mild symptoms. Fever and dyspnoea were less common than previously reported. A substantial proportion of SARS-CoV-2-positive people did not meet recommended case definitions at the time of diagnosis.
 
Back
Top Bottom